



US007959907B2

(12) **United States Patent**
Brouckaert et al.

(10) **Patent No.:** **US 7,959,907 B2**
(45) **Date of Patent:** **Jun. 14, 2011**

(54) **METHOD OF TREATING CANCER BY COMBINATION THERAPY USING TNF AND ALPHA-GALACTOSYLCERAMIDE**

(75) Inventors: **Peter Brouckaert**, Ghent (BE); **Dirk Elewaut**, Heusden (BE); **Leander Huyghe**, Aarsele (BE)

(73) Assignees: **VIB VZW**, Gent (BE); **Universiteit Gent**, Gent (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/449,652**

(22) PCT Filed: **Feb. 20, 2008**

(86) PCT No.: **PCT/EP2008/052055**

§ 371 (c)(1),
(2), (4) Date: **Dec. 17, 2009**

(87) PCT Pub. No.: **WO2008/101951**

PCT Pub. Date: **Aug. 28, 2008**

(65) **Prior Publication Data**

US 2010/0166697 A1 Jul. 1, 2010

(30) **Foreign Application Priority Data**

Feb. 21, 2007 (EP) 07102787

(51) **Int. Cl.**

A61K 45/00 (2006.01)

A61K 31/00 (2006.01)

A61K 38/00 (2006.01)

A01N 61/00 (2006.01)

(52) **U.S. Cl.** **424/85.1**; 514/1; 514/1.1

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,677,063 A 6/1987 Mark et al.
4,677,064 A 6/1987 Mark et al.
2004/0127429 A1 7/2004 Tsuji

FOREIGN PATENT DOCUMENTS

EP 609437 B1 7/1999
WO WO 97/12962 4/1997
WO WO 00/77168 A2 12/2000
WO WO 2005/003167 A1 1/2005
WO WO 2006/026389 3/2006
WO WO 2008/101951 A1 8/2008

OTHER PUBLICATIONS

Carswell EA, et al. Proc. Natl. Acad. Sci. 72(9):3666-3670, 1975.*

Giaccone G, et al. Clinical Cancer Research, vol. 8:3702-3709, 2002.*

Ten Hagen TLM, et al. Int. J. Cancer 87(6):829-837, 2000.*

Nakagawa R, et al. Cancer Research 58:1202-1207, Mar. 15, 1998.*

Mosteller RD. N. Engl. J. Med. Oct. 22, 1987;317(17):1098.*

PCT International Search Report, PCT/EP2008/052055, dated Jun. 30, 2008.

Inui et al., Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice, Journal of Hepatology, 2005, pp. 670-678, vol. 43.

Metelitsa et al., Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells, Leukemia, 2003, pp. 1068-1077, vol. 17.

Nakui et al., Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells, Clinical & Experimental Metastasis, 2000, pp. 147-153, vol. 18.

Nishi et al., Synergistic Effect of KRN7000 with Interleukin-15, -7, and -2 on the Expansion of Human Valpha24+Vbeta11+T Cells In Vitro. Human Immunology, 2000, pp. 357-365, vol. 61.

DeVita et al., Chapter 13, Biologic Therapy with TNF: Systemic Administration and Isolation-Perfusion, Biologic Therapy of Cancer, Second Edition, 1995, pp. 329-345.

Lejeune et al., Efficiency of recombinant human TNF in human cancer therapy, Cancer Immunity, Mar. 22, 2006, pp. 1-17, vol. 6, p. 6.

PCT International Search Report, PCT/EP2004/051327, dated Dec. 9, 2004.

PCT Written Opinion, PCT/EP2004/051327, dated Dec. 9, 2004.

Brown et al., "Regulation of TRAF2 Signaling by Self-Induced Degradation," The Journal of Biological Chemistry, May 31, 2002, pp. 19433-19438, vol. 277, No. 22.

Kavsak et al., "Samd7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGF-beta Receptor for Degradation," Molecular Cell, Dec. 2000, pp. 1365-1375, vol. 6.

Legler et al., "Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNF-alpha-Mediated NF-kappaB Activation," Immunity, May 2003, pp. 655-664, vol. 18.

Zapata et al., "TRAF1: Lord Without a RING," Science's STKE, May 21, 2002, pp. 1-5, vol. 2002, No. 133.

Fraker et al., Chapter 13, Biologic Therapy with TNF: Systemic Administration and Isolation-Perfusion, Biologic Therapy of Cancer, Second Edition, 1995, pp. 329-345.

Nakagawa et al., Treatment of Hepatic Metastasis of the Colon 26 adenocarcinoma with an alpha-Galactosylceramids, KRN7000, Cancer Research, Mar. 15, 1998, pp. 1202-07, vol. 58.

* cited by examiner

Primary Examiner — Robert Landsman

(74) Attorney, Agent, or Firm — TraskBritt, P.C.

(57) **ABSTRACT**

The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.

15 Claims, 2 Drawing Sheets